January 24, 2025

Sex and Age Influence Long COVID Risk

"These findings highlight the need to identify biological mechanisms contributing to sex specificity to facilitate risk stratification, targeted drug development, and improved management of long COVID," wrote the study's authors.

Conexiant

January 24, 2025

VA Study Maps GLP-1 Effects Across Systems

Large-scale study of 1.9M veterans identifies previously unreported benefits and risks of GLP-1 receptor agonists across 175 health outcomes, including reduced substance use disorders and increased pancreatitis risk.

Conexiant

January 23, 2025

Exploratory Metabolomic Study Identifies Potential SIDS Pathways

Potential biomarkers and metabolic pathways linked to sudden infant death syndrome were identified.

Conexiant

January 22, 2025

Phase 3 Data Evaluates New Dermatomyositis Measure

Data from a phase III trial demonstrate the sensitivity of a new composite measure in detecting treatment effects for skin and muscle disease activity in dermatomyositis.

Conexiant

January 22, 2025

Parkinson's Risk: New Findings 'Have Significant Implications'

Every 10 dB increase in speech-in-noise hearing impairment was associated with a 57% higher risk of developing Parkinson’s disease,

Conexiant

January 21, 2025

MIS-C Study: Six-Month Outcomes Highlight Recovery

By six months, 99% of MIS-C patients with reduced left ventricular systolic function had normalization, according to researchers.

Conexiant

January 21, 2025

Oral Dissolving Film Anticoagulant Trial Results

TAHO Pharmaceuticals completes pivotal trial of the first oral dissolving film anticoagulant, potentially transforming how life-saving therapies are delivered.

Conexiant

January 16, 2025

Vertigo, Emesis, Auditory Impairment: What's Your Diagnosis?

A patient presents with sudden-onset right-sided otalgia accompanied by vertigo, emesis, and auditory impairment. Your otoscope reveals an unexpected finding. What's your diagnosis?

Conexiant

January 16, 2025

New XLH Guidelines Shift Primary Therapy to Burosumab

"Burosumab treatment normalized ALP serum levels in about 80% of both pediatric and adolescent cohorts, suggesting a substantial improvement of rickets in these patients," report authors of comprehensive new evidence-based recommendations for X-linked hypophosphatemia management.

Conexiant